Inhibikase Therapeutics, Inc. (IKT)
| Market Cap | 20.18M |
| Revenue (ttm) | 1.74M |
| Net Income (ttm) | -16.79M |
| Shares Out | 25.23M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,503 |
| Open | 0.800 |
| Previous Close | 0.800 |
| Day's Range | 0.790 - 0.828 |
| 52-Week Range | 0.600 - 2.940 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 6.12 (+665.0%) |
| Earnings Date | Aug 15, 2022 |
About IKT
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib th... [Read more...]
Financial Performance
In 2021, IKT's revenue was $3.10 million, an increase of 343.92% compared to the previous year's $698,468. Losses were -$14.79 million, 419.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for IKT stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 665.00% from the latest price.
News
Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
Phase 1/1b '101' study terminated early; demonstrated favorable safety, tolerability, and pharmacokinetic profile in single doses up to 325 mg and multiple doses up to 100 mg Phase 2a '201' study open f...
Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
Company to host conference call and webcast on Tuesday, May 17, 2022, at 8:00am ET BOSTON and ATLANTA , May 16, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), ...
Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
BOSTON and ATLANTA , May 10, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkin...
Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
BOSTON and ATLANTA , May 9, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkins...
Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
BOSTON and ATLANTA , April 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Park...
Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022
BOSTON and ATLANTA , April 6, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the cour...
Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity
BOSTON and ATLANTA , March 31, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the cou...
Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit
BOSTON and ATLANTA , March 28, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Park...
Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022
BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkin...
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference
BOSTON and ATLANTA , March 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Park...
Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases...
BOSTON and ATLANTA, March 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkin...
Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones
BOSTON and ATLANTA, Jan. 5, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkins...
Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinas...
BOSTON and ATLANTA, Nov. 29, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the c...
Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
BOSTON and ATLANTA, Nov. 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkin...
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
ATLANTA, Oct. 19, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...
Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinas...
ATLANTA, Oct. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Par...
Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatme...
ATLANTA, Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of P...
Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
ATLANTA, Sept. 7, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...
Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
ATLANTA, Aug. 16, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...
Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients
ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Pa...
Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock
ATLANTA, June 18, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...
Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% Discount
Inhibikase Therapeutics Inc (NASDAQ: IKT) has priced an underwritten public offering of 15 million shares at $3/share for gross proceeds of approximately $45 million. The offer price represents a 26% di...
Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock
ATLANTA, June 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...
Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others
ATLANTA, May 25, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's diseas...